Attovia Therapeutics, Inc. (ATTO) Valuation | Quantisight AI

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-93.5%

$0.97

vs $15.05 price

Levered DCF

$0.41

After debt service

Piotroski score

—

Altman Z-score

—

Rating

C

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024
P/E	-15.42×	-20.86×
P/B	6.25×	15.17×
P/S	698.03×	0×
EV / EBITDA	-13.67×	-22.11×
Gross margin	40.4%	0.0%
Operating margin	-4974.7%	0.0%
Net margin	-4490.9%	0.0%
Current ratio	14.2×	9.39×
Debt / equity	0.03×	0×
Interest coverage	0×	0×
Dividend yield	0.0%	0.0%
Payout ratio	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024
Return on equity	-40.2%	-64.1%
Return on invested capital	-42.8%	-60.2%
Return on assets	-36.5%	-51.9%
Free cash flow yield	-6.5%	-3.9%
Earnings yield	-6.4%	-4.2%
Enterprise value	$907.4M	$911.7M
Net debt / EBITDA	0.53×	0.74×
Cash conversion cycle (days)	-1,612	-4,828